Phenotypes associated with this allele

• Allele Symbol: Gt(ROSA)26Sor^{tm2(cre/ERT2)Brn}
• Allele Name: targeted mutation 2, Anton Berns
• Allele ID: MGI:3764519
• Summary: 25 genotypes

Jump to	Allelic Composition	Genetic Background	Genotype ID
cn1	Gpx4^tm2Marc/Gpx4^tm2Marc Gt(ROSA)26Sor^tm2(cre/ERT2)Brn/0	involves: 129P2/OlaHsd	MGI:8350573
cn2	Pknox1^tm2.1Fbla/Pknox1^tm2.1Fbla Gt(ROSA)26Sor^tm2(cre/ERT2)Brn/Gt(ROSA)26Sor^+	involves: 129P2/OlaHsd	MGI:5469881
cn3	Bcl11a^tm2.1Peli/Bcl11a^tm2.1Peli Gt(ROSA)26Sor^tm2(cre/ERT2)Brn/Gt(ROSA)26Sor^+	involves: 129P2/OlaHsd * 129S1/Sv	MGI:5475382
cn4	Bcl11a^tm2.1Peli/Bcl11a^tm2.1Peli Trp53^tm1Brn/Trp53^tm1Brn Gt(ROSA)26Sor^tm2(cre/ERT2)Brn/Gt(ROSA)26Sor^+	involves: 129P2/OlaHsd * 129S1/Sv	MGI:5475383
cn5	Ptch1^tm1Hahn/Ptch1^tm1Hahn Gt(ROSA)26Sor^tm2(cre/ERT2)Brn/Gt(ROSA)26Sor^+	involves: 129P2/OlaHsd * 129S1/Sv * 129X1/SvJ	MGI:4452396
cn6	Ptch1^tm1Hahn/Ptch1^+ Gt(ROSA)26Sor^tm2(cre/ERT2)Brn/Gt(ROSA)26Sor^+	involves: 129P2/OlaHsd * 129S1/Sv * 129X1/SvJ * BALB/c * C57BL/6	MGI:5447639
cn7	Ptch1^tm1Hahn/Ptch1^tm1Hahn Gt(ROSA)26Sor^tm2(cre/ERT2)Brn/Gt(ROSA)26Sor^+	involves: 129P2/OlaHsd * 129S1/Sv * 129X1/SvJ * BALB/c * C57BL/6	MGI:5447637
cn8	Ptch1^tm1Hahn/Ptch1^tm1Hahn Gt(ROSA)26Sor^tm2(cre/ERT2)Brn/Gt(ROSA)26Sor^+	involves: 129P2/OlaHsd * 129S1/Sv * 129X1/SvJ * C57BL/6	MGI:3764626
cn9	Ptch1^tm1Hahn/Ptch1^+ Gt(ROSA)26Sor^tm2(cre/ERT2)Brn/Gt(ROSA)26Sor^+	involves: 129P2/OlaHsd * 129S1/Sv * 129X1/SvJ * C57BL/6	MGI:5447638
cn10	Foxn1^tm1.1Cbln/Foxn1^tm1Tbo Gt(ROSA)26Sor^tm2(cre/ERT2)Brn/Gt(ROSA)26Sor^+	involves: 129P2/OlaHsd * 129S1/Sv * C57BL/6	MGI:5297816
cn11	Prmt5^tm2c(EUCOMM)Wtsi/Prmt5^tm2c(EUCOMM)Wtsi Gt(ROSA)26Sor^tm2(cre/ERT2)Brn/Gt(ROSA)26Sor^+	involves: 129P2/OlaHsd * 129S1/SvlmJ * C57BL/6Brd * C57BL/6N * SJL	MGI:5546603
cn12	Nle1^tm1Cba/Nle1^tm1.1Cota Gt(ROSA)26Sor^tm2(cre/ERT2)Brn/Gt(ROSA)26Sor^+	involves: 129P2/OlaHsd * 129S2/SvPas	MGI:5553371
cn13	Nle1^tm1Cba/Nle1^tm1.1Cota Gt(ROSA)26Sor^tm2(cre/ERT2)Brn/Gt(ROSA)26Sor^+ Trp53^tm1Tyj/Trp53^tm1Tyj	involves: 129P2/OlaHsd * 129S2/SvPas	MGI:5553372
cn14	Zfp830^tm2.1Cota/Zfp830^tm2.2Cota Gt(ROSA)26Sor^tm2(cre/ERT2)Brn/?	involves: 129P2/OlaHsd * 129S2/SvPas * BALB/c * C57BL/6	MGI:4950720
cn15	Hdac1^tm1.1Mrl/Hdac1^tm1.1Mrl Hdac2^tm1.1Rdp/Hdac2^tm1.1Rdp Gt(ROSA)26Sor^tm2(cre/ERT2)Brn/Gt(ROSA)26Sor^+	involves: 129P2/OlaHsd * 129S4/SvJae * C57BL/6	MGI:5494632
cn16	Odad3^tm1c(EUCOMM)Hmgu/Odad3^tm1c(EUCOMM)Hmgu Gt(ROSA)26Sor^tm2(cre/ERT2)Brn/Gt(ROSA)26Sor^+	involves: 129P2/OlaHsd * 129S4/SvJaeSor * C57BL/6N	MGI:6360704
cn17	Gas2l3^tm1c(EUCOMM)Hmgu/Gas2l3^tm1c(EUCOMM)Hmgu Gt(ROSA)26Sor^tm2(cre/ERT2)Brn/Gt(ROSA)26Sor^+	involves: 129P2/OlaHsd * 129S4/SvJaeSor * C57BL/6N	MGI:6116291
cn18	Bcl11b^tm1Peli/Bcl11b^tm1Peli Gt(ROSA)26Sor^tm2(cre/ERT2)Brn/Gt(ROSA)26Sor^+	involves: 129P2/OlaHsd * 129S5/SvEvBrd * C57BL/6J	MGI:4818786
cn19	Dll4^tm2.1Vlcg/Dll4^+ Gt(ROSA)26Sor^tm2(cre/ERT2)Brn/Gt(ROSA)26Sor^+	involves: 129P2/OlaHsd * 129S6/SvEvTac * C57BL/6NTac	MGI:5302388
cn20	Rag1^tm1.1Sadu/Rag1^tm1.1Sadu Trdc^tm1Mal/Trdc^tm1Mal Gt(ROSA)26Sor^tm2(cre/ERT2)Brn/Gt(ROSA)26Sor^+	involves: 129P2/OlaHsd * BALB/c * C57BL/6	MGI:5438822
cn21	Gt(ROSA)26Sor^tm2(cre/ERT2)Brn/Gt(ROSA)26Sor^+ Pten^tm2Mak/Pten^tm2Mak Tg(RasE)290Biat/0	involves: 129P2/OlaHsd * C57BL/6 * DBA/2	MGI:5770439
cn22	Gt(ROSA)26Sor^tm2(cre/ERT2)Brn/Gt(ROSA)26Sor^+ Tg(RasE)290Biat/0	involves: 129P2/OlaHsd * C57BL/6 * DBA/2	MGI:5770438
cn23	Gpx4^em1Marc/Gpx4^tm2Marc Gt(ROSA)26Sor^tm2(cre/ERT2)Brn/0	involves: 129P2/OlaHsd * C57BL/6J	MGI:8350568
cn24	Gt(ROSA)26Sor^tm2(cre/ERT2)Brn/0 Tg(Sftpc-Grem1)105Mmyl/0	involves: 129P2/OlaHsd * C57BL/6N	MGI:5707181
cn25	Gt(ROSA)26Sor^tm2(cre/ERT2)Brn/Gt(ROSA)26Sor^+ Tg(GFP/KRAS2/ALPP)1Brn/0	involves: 129P2/OlaHsd * FVB/N	MGI:3765975

Genotype
MGI:8350573

cn1

• Allelic Composition: Gpx4^tm2Marc/Gpx4^tm2Marc; Gt(ROSA)26Sor^{tm2(cre/ERT2)Brn}/0
• Genetic Background: involves: 129P2/OlaHsd

• ♀: phenotype observed in females
• ♂: phenotype observed in males
• N: normal phenotype

cellular

increased ferroptosis ( J:385850 )

• renal proximal tubule epithelia cell death by ferroptosis after tamoxifen administration

growth/size/body

weight loss ( J:385850 )

• owing to acute kidney failure after tamoxifen administration

homeostasis/metabolism

increased circulating creatinine level ( J:385850 )

• after tamoxifen administration

increased circulating bilirubin level ( J:385850 )

• after tamoxifen administration

increased circulating alanine transaminase level ( J:385850 )

• after tamoxifen administration

increased circulating aspartate transaminase level ( J:385850 )

• after tamoxifen administration

increased circulating lactate dehydrogenase level ( J:385850 )

• after tamoxifen administration

decreased circulating serum albumin level ( J:385850 )

• after tamoxifen administration

increased blood urea nitrogen level ( J:385850 )

• after tamoxifen administration

mortality/aging

premature death ( J:385850 )

• acute kidney failure leads to death 10-12 after tamoxifen administration

renal/urinary system

renal necrosis ( J:385850 )

• renal proximal tubule epithelia cell death by ferroptosis after tamoxifen administration

Genotype
MGI:5469881

cn2

• Allelic Composition: Pknox1^tm2.1Fbla/Pknox1^tm2.1Fbla; Gt(ROSA)26Sor^{tm2(cre/ERT2)Brn}/Gt(ROSA)26Sor⁺
• Genetic Background: involves: 129P2/OlaHsd

hematopoietic system

increased pro-B cell number ( J:192251 )

• in tamoxifen-treated mice

decreased pre-B cell number ( J:192251 )

• in tamoxifen-treated mice

immune system

increased pro-B cell number ( J:192251 )

• in tamoxifen-treated mice

decreased pre-B cell number ( J:192251 )

• in tamoxifen-treated mice

Genotype
MGI:5475382

cn3

• Allelic Composition: Bcl11a^tm2.1Peli/Bcl11a^tm2.1Peli; Gt(ROSA)26Sor^{tm2(cre/ERT2)Brn}/Gt(ROSA)26Sor⁺
• Genetic Background: involves: 129P2/OlaHsd * 129S1/Sv

hematopoietic system

increased B cell apoptosis ( J:194616 )

• in pro-B, pre-B and immature B cells of tamoxifen-treated mice

• however, apoptosis is rescued by exogenous Bcl2 or Mdm2 and Bcl2

decreased pro-B cell number ( J:194616 )

• in the bone marrow of tamoxifen-treated mice

abnormal T cell differentiation ( J:194616 )

• few early T cell progenitors in the thymus of tamoxifen-treated mice

decreased DN2 thymocyte number ( J:194616 )

• in tamoxifen-treated mice

abnormal common lymphocyte progenitor cell morphology ( J:194616 )

• reduced 7-fold in tamoxifen-treated mice

decreased B cell number ( J:194616 )

• in the bone marrow of tamoxifen-treated mice

• however, the number of B cells in the spleen, lymph node and peripheral blood is normal

decreased immature B cell number ( J:194616 )

• to one-fifth of wild-type levels in the bone marrow of tamoxifen-treated mice

decreased pre-B cell number ( J:194616 )

• in the bone marrow of tamoxifen-treated mice

decreased hematopoietic stem cell number ( J:194616 )

• reduced LSK and lymphoid-primed multipotent progenitors in tamoxifen-treated mice

abnormal hematopoietic stem cell physiology ( J:194616 )

• tamoxifen-treated LSK cells exhibit a complete loss of lymphoid development

cellular

increased B cell apoptosis ( J:194616 )

• in pro-B, pre-B and immature B cells of tamoxifen-treated mice

• however, apoptosis is rescued by exogenous Bcl2 or Mdm2 and Bcl2

immune system

increased B cell apoptosis ( J:194616 )

• in pro-B, pre-B and immature B cells of tamoxifen-treated mice

• however, apoptosis is rescued by exogenous Bcl2 or Mdm2 and Bcl2

abnormal immune system morphology ( J:194616 )

• complete loss of lymphoid development in tamoxifen-treated bone marrow cells is cell autonomous

decreased pro-B cell number ( J:194616 )

• in the bone marrow of tamoxifen-treated mice

abnormal T cell differentiation ( J:194616 )

• few early T cell progenitors in the thymus of tamoxifen-treated mice

decreased DN2 thymocyte number ( J:194616 )

• in tamoxifen-treated mice

decreased B cell number ( J:194616 )

• in the bone marrow of tamoxifen-treated mice

• however, the number of B cells in the spleen, lymph node and peripheral blood is normal

decreased immature B cell number ( J:194616 )

• to one-fifth of wild-type levels in the bone marrow of tamoxifen-treated mice

decreased pre-B cell number ( J:194616 )

• in the bone marrow of tamoxifen-treated mice

endocrine/exocrine glands

decreased DN2 thymocyte number ( J:194616 )

• in tamoxifen-treated mice

Genotype
MGI:5475383

cn4

• Allelic Composition: Bcl11a^tm2.1Peli/Bcl11a^tm2.1Peli; Trp53^tm1Brn/Trp53^tm1Brn; Gt(ROSA)26Sor^{tm2(cre/ERT2)Brn}/Gt(ROSA)26Sor⁺
• Genetic Background: involves: 129P2/OlaHsd * 129S1/Sv

hematopoietic system

hematopoietic system phenotype ( J:194616 )

N • early B cell development is rescued in tamoxifen treated mice

decreased hematopoietic stem cell number ( J:194616 )

• reduced LSK and lymphoid-primed multipotent progenitors in tamoxifen-treated mice

abnormal hematopoietic stem cell physiology ( J:194616 )

• tamoxifen-treated LSK cells exhibit a complete loss of lymphoid development

immune system

immune system phenotype ( J:194616 )

N • early B cell development is rescued in tamoxifen treated mice

Genotype
MGI:4452396

cn5

• Allelic Composition: Ptch1^tm1Hahn/Ptch1^tm1Hahn; Gt(ROSA)26Sor^{tm2(cre/ERT2)Brn}/Gt(ROSA)26Sor⁺
• Genetic Background: involves: 129P2/OlaHsd * 129S1/Sv * 129X1/SvJ

neoplasm

increased basal cell carcinoma incidence ( J:158915 )

• after 45 days of tamoxifen treatment, mice exhibit visible tumors in the tails and ears unlike similarly treated wild-type mice

• 90 days after tamoxifen treatment, mice exhibit fully developed basal cell carcinomas (BCC) that are not invasive or aggressive over time

• BCCs likely originate from the outer root sheath of the hair follicle based on antibody staining

decreased tumor growth/size ( J:158915 )

• after 200 days of tamoxifen treatment tumors are smaller than fully developed basal cell carcinomas and exhibit decreased proliferation indicating regression

integument

increased basal cell carcinoma incidence ( J:158915 )

• after 45 days of tamoxifen treatment, mice exhibit visible tumors in the tails and ears unlike similarly treated wild-type mice

• 90 days after tamoxifen treatment, mice exhibit fully developed basal cell carcinomas (BCC) that are not invasive or aggressive over time

• BCCs likely originate from the outer root sheath of the hair follicle based on antibody staining

Mouse Models of Human Disease		DO ID	OMIM ID(s)	Ref(s)
basal cell carcinoma		DOID:2513		J:158915

Genotype
MGI:5447639

cn6

• Allelic Composition: Ptch1^tm1Hahn/Ptch1⁺; Gt(ROSA)26Sor^{tm2(cre/ERT2)Brn}/Gt(ROSA)26Sor⁺
• Genetic Background: involves: 129P2/OlaHsd * 129S1/Sv * 129X1/SvJ * BALB/c * C57BL/6

mortality/aging

premature death ( J:149148 )

• median survival in mice subjected to intramuscular treatment with 100 ug tamoxifen at 6 to 8 weeks is 326 days

Genotype
MGI:5447637

cn7

• Allelic Composition: Ptch1^tm1Hahn/Ptch1^tm1Hahn; Gt(ROSA)26Sor^{tm2(cre/ERT2)Brn}/Gt(ROSA)26Sor⁺
• Genetic Background: involves: 129P2/OlaHsd * 129S1/Sv * 129X1/SvJ * BALB/c * C57BL/6

mortality/aging

premature death ( J:149148 )

• median survival in mice subjected to intramuscular treatment with 100 ug tamoxifen at 6 to 8 weeks is 205 days

• median survival in mice subjected to intramuscular treatment with 100 ug tamoxifen at 6 to 8 weeks and 1 umol CTX is 171 days compared with 338 days for control mice

• median survival in mice subjected to intramuscular treatment 50 ug tamoxifen at 2 weeks is 160 days compared with 228 days for control mice

neoplasm

increased tumor incidence ( J:149148 )

• mice subjected to intramuscular treatment with 100 ug tamoxifen at 6 to 8 weeks or intramuscular treatment 50 ug tamoxifen at 2 weeks exhibit rare follicular tumors on the trunk and paws

increased basal cell carcinoma incidence ( J:149148 )

• in 10 of 10 mice subjected to intramuscular treatment with 100 ug tamoxifen at 6 to 8 weeks unlike control mice

• in 10 of 10 mice subjected to intramuscular treatment with 100 ug tamoxifen and 1 umol CTX at 6 to 8 weeks unlike control mice

• in 10 of 10 mice subjected to intramuscular treatment 50 ug tamoxifen at 2 weeks unlike control mice

integument

increased basal cell carcinoma incidence ( J:149148 )

• in 10 of 10 mice subjected to intramuscular treatment with 100 ug tamoxifen at 6 to 8 weeks unlike control mice

• in 10 of 10 mice subjected to intramuscular treatment with 100 ug tamoxifen and 1 umol CTX at 6 to 8 weeks unlike control mice

• in 10 of 10 mice subjected to intramuscular treatment 50 ug tamoxifen at 2 weeks unlike control mice

Genotype
MGI:3764626

cn8

• Allelic Composition: Ptch1^tm1Hahn/Ptch1^tm1Hahn; Gt(ROSA)26Sor^{tm2(cre/ERT2)Brn}/Gt(ROSA)26Sor⁺
• Genetic Background: involves: 129P2/OlaHsd * 129S1/Sv * 129X1/SvJ * C57BL/6

mortality/aging

premature death ( J:149148 )

• median survival in mice subjected to intramuscular treatment with 100 ug tamoxifen at 6 to 8 weeks is 205 days

• median survival in mice subjected to intramuscular treatment with 100 ug tamoxifen at 6 to 8 weeks and 1 umol CTX is 171 days compared with 338 days for control mice

• median survival in mice subjected to intramuscular treatment 50 ug tamoxifen at 2 weeks is 160 days compared with 228 days for control mice

immune system

abnormal thymus lobule morphology ( J:127207 )

• 19 days after the first injection of tamoxifen, the thymus has lost its regular morphology and the cortex is no longer distinguishable from the medulla

thymus hypoplasia ( J:127207 )

• 15 days after the first injection of tamoxifen, thymus cellularity is decreased by 13-fold

abnormal double-negative T cell morphology ( J:127207 )

• 19 days after the first injection of tamoxifen, the DN1 population is overrepresented while the DN2 and DN3 populations are underrepresented

• however, the DN4 population is stable after tamoxifen treatment

increased double-negative T cell number ( J:127207 )

• 19 days after the first injection of tamoxifen, the relative number of immature double positive cells is increased compared to in Ptch1^tm1Jwnd control mice

increased neutrophil cell number ( J:127207 )

• following treatment with tamoxifen, the number of neutrophilic granulocytes is increased compared to in Ptch1^tm1Jwnd control mice

increased B cell number ( J:127207 )

• following treatment with tamoxifen, circulating B220^high, IgD+ B cells are increased compared to in Ptch1^tm1Jwnd control mice

increased mature B cell number ( J:127207 )

• at day15 through 19 after the first injection of tamoxifen, mature B cells are overrepresented in the spleen compared to in Ptch1^tm1Jwnd control mice

increased single-positive T cell number ( J:127207 )

• 19 days after the first injection of tamoxifen, the relative number of mature single positive cells is increased compared to in Ptch1^tm1Jwnd control mice

decreased lymphocyte cell number ( J:127207 )

• following treatment with tamoxifen, total lymphocyte fraction in the bone marrow is only slightly decreased compared to in Ptch1^tm1Jwnd control mice

decreased double-positive T cell number ( J:127207 )

• 19 days after the first injection of tamoxifen, the number of double positive cells is almost depleted compared to in Ptch1^tm1Jwnd control mice

decreased B cell number ( J:127207 )

• at day15 through 19 after the first injection of tamoxifen, the number of B220+ B cells in the spleen is reduced (4.71+/-2.33% compared to 13.98+/-3.74% in Ptch1^tm1Jwnd control mice)

decreased immature B cell number ( J:127207 )

• following treatment with tamoxifen, CD43+ B cells are almost completely absent and fraction I and II immature B cells are decreased in the bone marrow compared to in Ptch1^tm1Jwnd control mice

decreased transitional stage B cell number ( J:127207 )

• at day15 through 19 after the first injection of tamoxifen, the number of T1 transitional B cells is reduced in the spleen compared to in Ptch1^tm1Jwnd control mice

decreased pre-B cell number ( J:127207 )

• following treatment with tamoxifen, bone marrow B220^low pre-B cells are lower than in Ptch1^tm1Jwnd control mice

neoplasm

increased tumor incidence ( J:149148 )

• mice subjected to intramuscular treatment with 100 ug tamoxifen at 6 to 8 weeks or intramuscular treatment 50 ug tamoxifen at 2 weeks exhibit rare follicular tumors on the trunk and paws

increased basal cell carcinoma incidence ( J:149148 )

• in 10 of 10 mice subjected to intramuscular treatment with 100 ug tamoxifen at 6 to 8 weeks unlike control mice

• in 10 of 10 mice subjected to intramuscular treatment with 100 ug tamoxifen and 1 umol CTX at 6 to 8 weeks unlike control mice

• in 10 of 10 mice subjected to intramuscular treatment 50 ug tamoxifen at 2 weeks unlike control mice

integument

increased basal cell carcinoma incidence ( J:149148 )

• in 10 of 10 mice subjected to intramuscular treatment with 100 ug tamoxifen at 6 to 8 weeks unlike control mice

• in 10 of 10 mice subjected to intramuscular treatment with 100 ug tamoxifen and 1 umol CTX at 6 to 8 weeks unlike control mice

• in 10 of 10 mice subjected to intramuscular treatment 50 ug tamoxifen at 2 weeks unlike control mice

hematopoietic system

abnormal hematopoietic system morphology/development ( J:127207 )

• however, granulocyte-macrophage lineage specification is normal following treatment with tamoxifen

• following treatment with tamoxifen, the Lin-c-kit^highSca-1^high population is increased while the population of Lin-c-kit^lowSca-1^low are underrepresented compared to in Ptch1^tm1Jwnd control mice

abnormal thymus lobule morphology ( J:127207 )

• 19 days after the first injection of tamoxifen, the thymus has lost its regular morphology and the cortex is no longer distinguishable from the medulla

thymus hypoplasia ( J:127207 )

• 15 days after the first injection of tamoxifen, thymus cellularity is decreased by 13-fold

abnormal double-negative T cell morphology ( J:127207 )

• 19 days after the first injection of tamoxifen, the DN1 population is overrepresented while the DN2 and DN3 populations are underrepresented

• however, the DN4 population is stable after tamoxifen treatment

increased double-negative T cell number ( J:127207 )

• 19 days after the first injection of tamoxifen, the relative number of immature double positive cells is increased compared to in Ptch1^tm1Jwnd control mice

increased neutrophil cell number ( J:127207 )

• following treatment with tamoxifen, the number of neutrophilic granulocytes is increased compared to in Ptch1^tm1Jwnd control mice

increased B cell number ( J:127207 )

• following treatment with tamoxifen, circulating B220^high, IgD+ B cells are increased compared to in Ptch1^tm1Jwnd control mice

increased mature B cell number ( J:127207 )

• at day15 through 19 after the first injection of tamoxifen, mature B cells are overrepresented in the spleen compared to in Ptch1^tm1Jwnd control mice

increased single-positive T cell number ( J:127207 )

• 19 days after the first injection of tamoxifen, the relative number of mature single positive cells is increased compared to in Ptch1^tm1Jwnd control mice

decreased lymphocyte cell number ( J:127207 )

• following treatment with tamoxifen, total lymphocyte fraction in the bone marrow is only slightly decreased compared to in Ptch1^tm1Jwnd control mice

decreased double-positive T cell number ( J:127207 )

• 19 days after the first injection of tamoxifen, the number of double positive cells is almost depleted compared to in Ptch1^tm1Jwnd control mice

decreased B cell number ( J:127207 )

• at day15 through 19 after the first injection of tamoxifen, the number of B220+ B cells in the spleen is reduced (4.71+/-2.33% compared to 13.98+/-3.74% in Ptch1^tm1Jwnd control mice)

decreased immature B cell number ( J:127207 )

• following treatment with tamoxifen, CD43+ B cells are almost completely absent and fraction I and II immature B cells are decreased in the bone marrow compared to in Ptch1^tm1Jwnd control mice

decreased transitional stage B cell number ( J:127207 )

• at day15 through 19 after the first injection of tamoxifen, the number of T1 transitional B cells is reduced in the spleen compared to in Ptch1^tm1Jwnd control mice

decreased pre-B cell number ( J:127207 )

• following treatment with tamoxifen, bone marrow B220^low pre-B cells are lower than in Ptch1^tm1Jwnd control mice

endocrine/exocrine glands

abnormal thymus lobule morphology ( J:127207 )

• 19 days after the first injection of tamoxifen, the thymus has lost its regular morphology and the cortex is no longer distinguishable from the medulla

thymus hypoplasia ( J:127207 )

• 15 days after the first injection of tamoxifen, thymus cellularity is decreased by 13-fold

Genotype
MGI:5447638

cn9

• Allelic Composition: Ptch1^tm1Hahn/Ptch1⁺; Gt(ROSA)26Sor^{tm2(cre/ERT2)Brn}/Gt(ROSA)26Sor⁺
• Genetic Background: involves: 129P2/OlaHsd * 129S1/Sv * 129X1/SvJ * C57BL/6

mortality/aging

premature death ( J:149148 )

• median survival in mice subjected to intraperitoneal treatment with 5 mg tamoxifen at 8 weeks is 376 days compared with 441 days for control mice

neoplasm

increased tumor incidence ( J:149148 )

• hamartomatous gastrointestinal cystic tumors in 4 of 32 mice subjected to intraperitoneal treatment with 5 mg tamoxifen at 8 weeks unlike control mice

increased fibroma incidence ( J:149148 )

• in 1 of 32 mice subjected to intraperitoneal treatment with 5 mg tamoxifen at 8 weeks unlike control mice

integument

epidermal cyst ( J:149148 )

• epidermal cysts in 1 of 32 mice subjected to intraperitoneal treatment with 5 mg tamoxifen at 8 weeks unlike control mice

growth/size/body

epidermal cyst ( J:149148 )

• epidermal cysts in 1 of 32 mice subjected to intraperitoneal treatment with 5 mg tamoxifen at 8 weeks unlike control mice

Genotype
MGI:5297816

cn10

• Allelic Composition: Foxn1^tm1.1Cbln/Foxn1^tm1Tbo; Gt(ROSA)26Sor^{tm2(cre/ERT2)Brn}/Gt(ROSA)26Sor⁺
• Genetic Background: involves: 129P2/OlaHsd * 129S1/Sv * C57BL/6

immune system

immune system phenotype ( J:177992 )

N • restoration of normal thymus if cre induction with tamoxiphen occurs before 4 months of age

Genotype
MGI:5546603

cn11

• Allelic Composition: Prmt5^{tm2c(EUCOMM)Wtsi}/Prmt5^{tm2c(EUCOMM)Wtsi}; Gt(ROSA)26Sor^{tm2(cre/ERT2)Brn}/Gt(ROSA)26Sor⁺
• Genetic Background: involves: 129P2/OlaHsd * 129S1/SvlmJ * C57BL/6Brd * C57BL/6N * SJL
• Cell Lines: EPD0160_2_A08

embryo

embryonic growth retardation ( J:201152 )

• at E15.5 following tamoxifen treatment at E10.5

decreased embryo size ( J:201152 )

• at E15.5 following tamoxifen treatment at E10.5

integument

pallor ( J:201152 )

• at E15.5 following tamoxifen treatment at E10.5

growth/size/body

embryonic growth retardation ( J:201152 )

• at E15.5 following tamoxifen treatment at E10.5

decreased embryo size ( J:201152 )

• at E15.5 following tamoxifen treatment at E10.5

Genotype
MGI:5553371

cn12

• Allelic Composition: Nle1^tm1Cba/Nle1^tm1.1Cota; Gt(ROSA)26Sor^{tm2(cre/ERT2)Brn}/Gt(ROSA)26Sor⁺
• Genetic Background: involves: 129P2/OlaHsd * 129S2/SvPas

Severe hypocellularity in Nle1^tm1Cba/Nle1^tm1.1Cota Gt(ROSA)26Sor^{tm2(cre/ERT2)Brn}/Gt(ROSA)26Sor⁺ bone marrow, with capillaries saturated with erythrocytes

mortality/aging

premature death ( J:204063 )

• mice die 10 to 13 days after tamoxifen treatment

immune system

decreased granulocyte number ( J:204063 )

• in tamoxifen-treated mice

decreased NK cell number ( J:204063 )

• in tamoxifen-treated mice

decreased T cell number ( J:204063 )

• in tamoxifen-treated mice

decreased macrophage cell number ( J:204063 )

• in tamoxifen-treated mice

abnormal immune system organ morphology ( J:204063 )

• defects in secondary lymphoid organs in tamoxifen-treated mice

thymus hypoplasia ( J:204063 )

• in tamoxifen-treated mice

spleen hypoplasia ( J:204063 )

• in tamoxifen-treated mice

digestive/alimentary system

abnormal intestinal epithelium morphology ( J:204063 )

• 7 to 9 days after tamoxifen treatment

cellular

abnormal ribosome biogenesis ( J:204063 )

• tamoxifen-treated mice exhibit impaired biogenesis of large ribosomal subunit in hematopoietic stem cell and multipotent progenitor compared with control mice

hematopoietic system

hematopoietic system phenotype ( J:204063 )

N • hematopoietic stem cell mobilization occurs normally in tamoxifen-treated mice

thymus hypoplasia ( J:204063 )

• in tamoxifen-treated mice

impaired hematopoiesis ( J:204063 )

• tamoxifen-treated mice exhibit cell autonomous defects in hematopoiesis

abnormal bone marrow cell morphology/development ( J:204063 )

• in tamoxifen-treated mice

• tamoxifen-treated mice exhibit impaired biogenesis of large ribosomal subunit in hematopoietic stem cell and multipotent progenitor compared with control mice

decreased common myeloid progenitor cell number ( J:204063 )

• in tamoxifen-treated mice

decreased bone marrow cell number ( J:204063 )

• severe in tamoxifen-treated mice

abnormal common lymphocyte progenitor cell morphology ( J:204063 )

• decreased in tamoxifen-treated mice

decreased granulocyte number ( J:204063 )

• in tamoxifen-treated mice

decreased NK cell number ( J:204063 )

• in tamoxifen-treated mice

decreased T cell number ( J:204063 )

• in tamoxifen-treated mice

decreased macrophage cell number ( J:204063 )

• in tamoxifen-treated mice

spleen hypoplasia ( J:204063 )

• in tamoxifen-treated mice

abnormal hematopoietic stem cell physiology ( J:204063 )

• reduced hematopoietic stem cell and multipotent progenitor quiescence in tamoxifen-treated mice

endocrine/exocrine glands

thymus hypoplasia ( J:204063 )

• in tamoxifen-treated mice

Genotype
MGI:5553372

cn13

• Allelic Composition: Nle1^tm1Cba/Nle1^tm1.1Cota; Gt(ROSA)26Sor^{tm2(cre/ERT2)Brn}/Gt(ROSA)26Sor⁺; Trp53^tm1Tyj/Trp53^tm1Tyj
• Genetic Background: involves: 129P2/OlaHsd * 129S2/SvPas

hematopoietic system

hematopoietic system phenotype ( J:204063 )

N • tamoxifen-treated mice exhibit rescued total bone marrow and LSK cells

Genotype
MGI:4950720

cn14

• Allelic Composition: Zfp830^tm2.1Cota/Zfp830^tm2.2Cota; Gt(ROSA)26Sor^{tm2(cre/ERT2)Brn}/?
• Genetic Background: involves: 129P2/OlaHsd * 129S2/SvPas * BALB/c * C57BL/6

cellular

decreased cell proliferation ( J:171647 )

• in tamoxifen-treated fibroblasts

early cellular replicative senescence ( J:171647 )

• proliferation of mouse embryonic fibroblasts is arrested 24 hours after tamoxifen-treatment unlike in control cells

Genotype
MGI:5494632

cn15

• Allelic Composition: Hdac1^tm1.1Mrl/Hdac1^tm1.1Mrl; Hdac2^tm1.1Rdp/Hdac2^tm1.1Rdp; Gt(ROSA)26Sor^{tm2(cre/ERT2)Brn}/Gt(ROSA)26Sor⁺
• Genetic Background: involves: 129P2/OlaHsd * 129S4/SvJae * C57BL/6

cellular

abnormal mitosis ( J:197818 )

• tamoxifen-treated mouse embryonic fibroblasts exhibit a 2-fold reduction in S-phase cells and an increase in G1 phase cell compared with control cells

decreased fibroblast proliferation ( J:197818 )

• tamoxifen-treated mouse embryonic fibroblasts exhibit growth arrest compared with control cells

early cellular replicative senescence ( J:197818 )

• in tamoxifen-treated mouse embryonic fibroblasts

Genotype
MGI:6360704

cn16

• Allelic Composition: Odad3^{tm1c(EUCOMM)Hmgu}/Odad3^{tm1c(EUCOMM)Hmgu}; Gt(ROSA)26Sor^{tm2(cre/ERT2)Brn}/Gt(ROSA)26Sor⁺
• Genetic Background: involves: 129P2/OlaHsd * 129S4/SvJaeSor * C57BL/6N

reproductive system

oligozoospermia ( J:278798 )

♂ • in tamoxifen-treated mice

asthenozoospermia ( J:278798 )

♂ • in tamoxifen-treated mice

cellular

oligozoospermia ( J:278798 )

♂ • in tamoxifen-treated mice

asthenozoospermia ( J:278798 )

♂ • in tamoxifen-treated mice

Genotype
MGI:6116291

cn17

• Allelic Composition: Gas2l3^{tm1c(EUCOMM)Hmgu}/Gas2l3^{tm1c(EUCOMM)Hmgu}; Gt(ROSA)26Sor^{tm2(cre/ERT2)Brn}/Gt(ROSA)26Sor⁺
• Genetic Background: involves: 129P2/OlaHsd * 129S4/SvJaeSor * C57BL/6N

cardiovascular system

cardiovascular system phenotype ( J:244087 )

N • no increase in heart weight, no dilation, and no fibrosis when tamoxifen is used to induce loss of expression in neonatal mice unlike when expression is absent in embryonic stages

abnormal fetal cardiomyocyte morphology ( J:244087 )

• in cultured cardiomyocytes after tamoxifen induction 22% become binucleated while very few cells were binucleate before tamoxifen exposure

abnormal fetal cardiomyocyte proliferation ( J:244087 )

• increase in the proportion of cardiomyocytes with unresolved cytokinetic midbody structures indicating failed abscission

cellular

abnormal fetal cardiomyocyte proliferation ( J:244087 )

• increase in the proportion of cardiomyocytes with unresolved cytokinetic midbody structures indicating failed abscission

abnormal mitotic cytokinesis ( J:244087 )

• increase in the proportion of cardiomyocytes with unresolved cytokinetic midbody structures indicating failed abscission

muscle

abnormal fetal cardiomyocyte proliferation ( J:244087 )

• increase in the proportion of cardiomyocytes with unresolved cytokinetic midbody structures indicating failed abscission

Genotype
MGI:4818786

cn18

• Allelic Composition: Bcl11b^tm1Peli/Bcl11b^tm1Peli; Gt(ROSA)26Sor^{tm2(cre/ERT2)Brn}/Gt(ROSA)26Sor⁺
• Genetic Background: involves: 129P2/OlaHsd * 129S5/SvEvBrd * C57BL/6J

immune system

abnormal NK cell differentiation ( J:161373 )

• cultured tamoxifen-treated DN1, DN2, and DN3 thymocytes differentiate into natural killer-like cells and kill stromal feeder cells unlike similarly treated wild-type thymocytes

• cultured spleen and thymus cells treated with tamoxifen exhibit differentiation into induced T to natural killer cells (ITNK) unlike cells from similarly treated wild-type cells

• tamoxifen-treated thymocytes transplanted into Rag2 Il2rg null mice exhibit an increase in ITNK cells compared with mice transplanted with similarly treated wild-type mice

neoplasm

decreased metastatic potential ( J:161373 )

• reprogrammed induced T to natural killer cells (ITNK) transplanted into Rag2 Il2rg null suppress metastasis of transplanted B16F10 melanoma cells

hematopoietic system

abnormal NK cell differentiation ( J:161373 )

• cultured tamoxifen-treated DN1, DN2, and DN3 thymocytes differentiate into natural killer-like cells and kill stromal feeder cells unlike similarly treated wild-type thymocytes

• cultured spleen and thymus cells treated with tamoxifen exhibit differentiation into induced T to natural killer cells (ITNK) unlike cells from similarly treated wild-type cells

• tamoxifen-treated thymocytes transplanted into Rag2 Il2rg null mice exhibit an increase in ITNK cells compared with mice transplanted with similarly treated wild-type mice

Genotype
MGI:5302388

cn19

• Allelic Composition: Dll4^tm2.1Vlcg/Dll4⁺; Gt(ROSA)26Sor^{tm2(cre/ERT2)Brn}/Gt(ROSA)26Sor⁺
• Genetic Background: involves: 129P2/OlaHsd * 129S6/SvEvTac * C57BL/6NTac

cardiovascular system

abnormal induced retina neovascularization ( J:177797 )

• retinal capillaries from tamoxifen-treated mice are more resistant to oxygen-induced vaso-obliteration compared with control capillaries

abnormal vascular regression ( J:177797 )

• tamoxifen-treated mice exhibit reduced capillary regression during normal developmental capillary remodeling compared with control mice

vision/eye

abnormal induced retina neovascularization ( J:177797 )

• retinal capillaries from tamoxifen-treated mice are more resistant to oxygen-induced vaso-obliteration compared with control capillaries

cellular

abnormal vascular regression ( J:177797 )

• tamoxifen-treated mice exhibit reduced capillary regression during normal developmental capillary remodeling compared with control mice

Genotype
MGI:5438822

cn20

• Allelic Composition: Rag1^tm1.1Sadu/Rag1^tm1.1Sadu; Trdc^tm1Mal/Trdc^tm1Mal; Gt(ROSA)26Sor^{tm2(cre/ERT2)Brn}/Gt(ROSA)26Sor⁺
• Genetic Background: involves: 129P2/OlaHsd * BALB/c * C57BL/6

immune system

small thymus ( J:187400 )

• in un-induced mice

• however, tamoxifen induction rescues thymus size

decreased gamma-delta T cell number ( J:187400 )

• Vgamma4+ gamma delta T cells in the peripheral lymph nodes, spleen, lung and liver despite tamoxifen treatment of adult mice

absent gamma-delta T cells ( J:187400 )

• absent IL17+ cells despite tamoxifen treatment of adult mice

increased gamma-delta T cell number ( J:187400 )

• Vgamma1+ gamma delta T cells in the spleen, lung and liver despite tamoxifen treatment of adult mice

hematopoietic system

small thymus ( J:187400 )

• in un-induced mice

• however, tamoxifen induction rescues thymus size

decreased gamma-delta T cell number ( J:187400 )

• Vgamma4+ gamma delta T cells in the peripheral lymph nodes, spleen, lung and liver despite tamoxifen treatment of adult mice

absent gamma-delta T cells ( J:187400 )

• absent IL17+ cells despite tamoxifen treatment of adult mice

increased gamma-delta T cell number ( J:187400 )

• Vgamma1+ gamma delta T cells in the spleen, lung and liver despite tamoxifen treatment of adult mice

endocrine/exocrine glands

small thymus ( J:187400 )

• in un-induced mice

• however, tamoxifen induction rescues thymus size

Genotype
MGI:5770439

cn21

• Allelic Composition: Gt(ROSA)26Sor^{tm2(cre/ERT2)Brn}/Gt(ROSA)26Sor⁺; Pten^tm2Mak/Pten^tm2Mak; Tg(RasE)290Biat/0
• Genetic Background: involves: 129P2/OlaHsd * C57BL/6 * DBA/2

mortality/aging

premature death ( J:226601 )

• tamoxifen treated mice exhibit shortened lifespan

neoplasm

increased pancreas tumor incidence ( J:226601 )

• tamoxifen treated mice exhibit accelerated formation of lung and pancreatic tumors compared to single Tg(RasE)290Biat transgenics

increased lung tumor incidence ( J:226601 )

• tamoxifen treated mice exhibit accelerated formation of lung and pancreatic tumors compared to single Tg(RasE)290Biat transgenics

endocrine/exocrine glands

increased pancreas tumor incidence ( J:226601 )

• tamoxifen treated mice exhibit accelerated formation of lung and pancreatic tumors compared to single Tg(RasE)290Biat transgenics

respiratory system

increased lung tumor incidence ( J:226601 )

• tamoxifen treated mice exhibit accelerated formation of lung and pancreatic tumors compared to single Tg(RasE)290Biat transgenics

Genotype
MGI:5770438

cn22

• Allelic Composition: Gt(ROSA)26Sor^{tm2(cre/ERT2)Brn}/Gt(ROSA)26Sor⁺; Tg(RasE)290Biat/0
• Genetic Background: involves: 129P2/OlaHsd * C57BL/6 * DBA/2

neoplasm

increased sebaceous gland tumor incidence ( J:226601 )

• about 80% of tamoxifen-injected mice develop tumors in the skin which immunohistochemistry suggests are skin-appendage tumors derived from sebaceous glands

• skin-appendage tumors develop when 4-OH tamoxifen is applied atopically onto the back of the skin; 98.3% of tumors show simultaneous activation of the three alleles

increased pancreas tumor incidence ( J:226601 )

• 100% of mice develop lung and pancreatic cancers at between 8 and 12 weeks after tamoxifen injection

increased pancreatic ductal adenocarcinoma incidence ( J:226601 )

• pancreatic tumors of tamoxifen treated mice are intraepithelial neoplasias or pancreatic ductal adenocarcinomas

increased pancreatic intraepithelial neoplasia incidence ( J:226601 )

• pancreatic tumors of tamoxifen treated mice are intraepithelial neoplasias or pancreatic ductal adenocarcinomas

increased lung tumor incidence ( J:226601 )

• 100% of mice develop lung and pancreatic cancers at between 8 and 12 weeks after tamoxifen injection

increased lung adenocarcinoma incidence ( J:226601 )

• lung tumors of tamoxifen treated mice are adenocarcinomas

endocrine/exocrine glands

increased sebaceous gland tumor incidence ( J:226601 )

• about 80% of tamoxifen-injected mice develop tumors in the skin which immunohistochemistry suggests are skin-appendage tumors derived from sebaceous glands

• skin-appendage tumors develop when 4-OH tamoxifen is applied atopically onto the back of the skin; 98.3% of tumors show simultaneous activation of the three alleles

increased pancreas tumor incidence ( J:226601 )

• 100% of mice develop lung and pancreatic cancers at between 8 and 12 weeks after tamoxifen injection

increased pancreatic ductal adenocarcinoma incidence ( J:226601 )

• pancreatic tumors of tamoxifen treated mice are intraepithelial neoplasias or pancreatic ductal adenocarcinomas

increased pancreatic intraepithelial neoplasia incidence ( J:226601 )

• pancreatic tumors of tamoxifen treated mice are intraepithelial neoplasias or pancreatic ductal adenocarcinomas

respiratory system

increased lung tumor incidence ( J:226601 )

• 100% of mice develop lung and pancreatic cancers at between 8 and 12 weeks after tamoxifen injection

increased lung adenocarcinoma incidence ( J:226601 )

• lung tumors of tamoxifen treated mice are adenocarcinomas

integument

increased sebaceous gland tumor incidence ( J:226601 )

• about 80% of tamoxifen-injected mice develop tumors in the skin which immunohistochemistry suggests are skin-appendage tumors derived from sebaceous glands

• skin-appendage tumors develop when 4-OH tamoxifen is applied atopically onto the back of the skin; 98.3% of tumors show simultaneous activation of the three alleles

Genotype
MGI:8350568

cn23

• Allelic Composition: Gpx4^em1Marc/Gpx4^tm2Marc; Gt(ROSA)26Sor^{tm2(cre/ERT2)Brn}/0
• Genetic Background: involves: 129P2/OlaHsd * C57BL/6J

cellular

increased ferroptosis ( J:385850 )

• renal proximal tubule epithelia cell death by ferroptosis after tamoxifen administration

growth/size/body

weight loss ( J:385850 )

• owing to acute kidney failure after tamoxifen administration

homeostasis/metabolism

increased circulating creatinine level ( J:385850 )

• after tamoxifen administration

increased circulating bilirubin level ( J:385850 )

• after tamoxifen administration

increased circulating alanine transaminase level ( J:385850 )

• after tamoxifen administration

increased circulating aspartate transaminase level ( J:385850 )

• after tamoxifen administration

increased circulating lactate dehydrogenase level ( J:385850 )

• after tamoxifen administration

decreased circulating serum albumin level ( J:385850 )

• after tamoxifen administration

increased blood urea nitrogen level ( J:385850 )

• after tamoxifen administration

mortality/aging

premature death ( J:385850 )

• acute kidney failure leads to death 10-12 after tamoxifen administration

renal/urinary system

renal necrosis ( J:385850 )

• renal proximal tubule epithelia cell death by ferroptosis after tamoxifen administration

Genotype
MGI:5707181

cn24

• Allelic Composition: Gt(ROSA)26Sor^{tm2(cre/ERT2)Brn}/0; Tg(Sftpc-Grem1)105Mmyl/0
• Genetic Background: involves: 129P2/OlaHsd * C57BL/6N

immune system

lung inflammation ( J:82809 )

• following exposure to silica, the lung tissue of these mice exhibits significantly less inflammatory cell infiltration than that of wild-type mice.

respiratory system

lung inflammation ( J:82809 )

• following exposure to silica, the lung tissue of these mice exhibits significantly less inflammatory cell infiltration than that of wild-type mice.

abnormal pulmonary alveolar system morphology ( J:82809 )

• at 6 months of age, these mice may exhibit some alveolar space enlargement

thick pulmonary interalveolar septum ( J:82809 )

• at 6 months of age, these mice exhibit mild septal thickening

pulmonary fibrosis ( J:82809 )

• the lungs of these mice exhibit no histologically apparent alterations in fibrosis following exposure to silica

Genotype
MGI:3765975

cn25

• Allelic Composition: Gt(ROSA)26Sor^{tm2(cre/ERT2)Brn}/Gt(ROSA)26Sor⁺; Tg(GFP/KRAS2/ALPP)1Brn/0
• Genetic Background: involves: 129P2/OlaHsd * FVB/N

neoplasm

increased keratoacanthoma incidence ( J:127226 )

• upon induction with 4-hydroxytamoxifen (4-OHTA), 2/4 mice develop regional keratoacanthomas at site of drug application within 8 weeks

increased lymphoma incidence ( J:127226 )

• 2/4 induced animals acquire lymphoma

increased lung tumor incidence ( J:127226 )

• 2/4 induced animals acquire lung tumors

integument

increased keratoacanthoma incidence ( J:127226 )

• upon induction with 4-hydroxytamoxifen (4-OHTA), 2/4 mice develop regional keratoacanthomas at site of drug application within 8 weeks

respiratory system

increased lung tumor incidence ( J:127226 )

• 2/4 induced animals acquire lung tumors